This email address is being protected from spambots. You need JavaScript enabled to view it.

Science Behind Compounding

Technology, scientific knowledge, and research are crucial to therapeutic innovations - and vital parts of PCCA's Research and Development Team.

Our Goal

is to provide the most effective, innovative, and functional products for the compounding industry. In that spirit, we have committed significant resources to the study and validation of our technology.

We accomplish this by applying basic science to our research, with the goals of improving therapeutic options and advancing the profession through the publication of scholarly articles. Behind every study and product, there is a team of PhD-level scientists, chemists, and pharmacists dedicated in their pursuit of unsurpassed product innovation.

Optimized in Google Chrome or Mozilla Firefox. If you have issues accessing information on the website, please contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

News

Evaluation of Naltrexone HCl 1% Topical Cream applied to Psoriasis Tissue In Vitro

The purpose of this study is to evaluate the in vitro antiinflammatory and antiproliferative properties of Naltrexone HCl 1% Topical Cream (XemaTop™) (PCCA Formula 11934) applied to psoriasis tissue using reconstructed psoriasis tissue model, a 3- dimensional (3D) model obtained from human skin tissue specimens with the following characteristics: increased cellular proliferation and cytokine release, and presence of psoriasisassociated biomarkers. - View

Evaluation of Pentoxifylline 10% Topical Cream applied to Psoriasis Tissue In Vitro

The purpose of this study is to evaluate the in vitro antipsoriatic properties of Pentoxifylline 10% Topical Cream (XemaTop™) (PCCA Formula 12374) using a 3-dimensional (3D) reconstructed psoriasis tissue model. - View

denotes an impact-factor scientific journal.
denotes a publication authored by PCCA.

Sort by Category: 

Choose a Product:  

Lipoderm

PracaSil-Plus

SuspendIt

XemaTop

Equipment

Others

LoxaSperse

LoxOral

MucoLox

PracaSil-Plus

RheoSpray

SuspendIt

XemaTop

XyliFos

Do you have a Case Study you would like to submit?

If you would like to submit a case study, follow the button below to submit.

Submit Case Study

denotes an impact-factor scientific journal.
denotes a publication authored by PCCA.

Lipoderm

Jump to organization:  

EUPFI

European Paediatric Formulation Initiative

PCCA is the exclusive sponsor of the best poster and oral presentations at the EuPFI annual scientific conference

8th EuPFI Conference: Lisbon (Portugal) 21st-22nd September, 2016

  • Poster #1: A Novel Approach to Assess and Improve Palatability of an Inhaled Asset Using the Rat Brief Access Taste Aversion Assay and an In Silico Model of Salivary Flow

  • Poster #2: Palatability and Acceptability of Multiparticulate Formulations: Adults vs. Children Comparison

  • Poster #3: Simulating Different Dosing Scenarios for a Paediatric Valproic Acid ER Formulation in a New Paediatric Multistage Dissolution Model

  • Poster #4: Development and Evaluation of Taste-Masked Pediatric Minitablet Formulations with Bitter Model Drugs

7th EuPFI Conference: Antwerp (Belgium) 16th-17th September, 2015

  • Poster #1: Thin Substrates Manufactured by the Means of 3D-Printing-Tailor-Made Drug Delivery Systems for Paediatric Use

  • Poster #2: Preliminary Development of a Tool Assessing the Acceptability of Medicines for Paediatric Use

  • Poster #3: Can Solubilizing Excipients be Used with the Rat BATA Model to Assess the Taste of Poorly Water-Soluble Drugs?

6th EuPFI Conference: Athens (Greece) 17th-18th September, 2014

  • Poster #1: Development and Characterization of Dispersible Tablets Employing Novel Characterization Methods

  • Poster #2: Assessing the Taste of Medicines with Rodents: the In Vivo Rat Brief-Access Taste Aversion (BATA) Model

  • Poster #3: Monitoring Food and Fluid Intake as a Basis for Establishing Biorelevant Dissolution Methods for Children in the Age of 1 - 6 Years

5th EuPFI Conference: Barcelona (Spain) 18th-19th September, 2013

  • Poster #1: Immediate-Release Carbamazepine Formulations for Individual Dosing by the Solid Dosage Pen

  • Poster #2: Development of Buccal Films as Novel Dosage Form for Paediatric Use

  • Poster #3: End-User Perceptions of Solid Oral Dosage Forms in the UK and Canada Part 1: School Children and Adolescents

FIP

International Pharmaceutical Federation

PCCA was the exclusive sponsor of the compounding session: The Role of Compounding in Closing Therapeutic Gaps. This 6-hour session included expert speakers from the USA, Portugal, Germany and Spain, who brought together the various compounding specialties, considerations, guidelines and standards.

73rd FIP World Congress: Dublin (Ireland) 31st August – 5th September, 2013

IPSF

International Pharmaceutical Students’ Federation

PCCA has established a partnership with the IPSF as the official sponsor of the compounding events at the World Congress and Regional Symposia. The IPSF acknowledges the importance and necessity of compounding skills within the pharmacy profession and has created this grant, with the support of PCCA, to allow students around the world the chance to organize their own compounding events.

IPSF Development Fund Compounding Event (CE) Grant

In 2016, PCCA was the proud sponsor of the following CE:

  • 5th IPSF African Pharmaceutical Symposium: Kenya
  • 62nd IPSF World Congress: Zimbabwe

PCCA was acknowledged in the IPSF Press Release

PCCA was acknowledged in the IPSF Newsletter 107

EUPFI

European Paediatric Formulation Initiative

9th EuPFI Conference: Warsaw (Poland) 20th-21st September, 2017

  • Poster #1: Case Report of a Skin Viral Infection Treated with a Topical Extemporaneous Preparation

  • Poster #2: Physical and Chemical Stability of Phenobarbital 1mg/mL and 50 mg/mL Oral Suspensions (SuspendIt™)